Cidara Therapeutics to Participate in September Investor Conferences
Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its participation in two upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 4:00 PM ET, and participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 7:00 AM ET. Management will also conduct one-on-one meetings with investors during both events.
Details
News Market Reaction – CDTX
On Sep 4, the day this news came out, CDTX closed 2.36% above the previous close.
Data tracked by StockTitan Argus for the Sep 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences.
Details are as follows:
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8, 2025
Time: 4:00 PM ET
Format: Corporate Presentation
Event: Morgan Stanley 23rd Annual Global Healthcare Conference
Date: September 9, 2025
Time: 7:00 AM ET
Format: Fireside Chat
Cidara will also participate in one-on-one investor meetings during the conferences.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.